Cytokinetics (CYTK) PT Raised to $33 at Piper Sandler, After Licensing Collaboration Announced
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $67.56 -1.77%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff raised the price target on Cytokinetics (NASDAQ: CYTK) to $33.00 (from $28.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Candel Therapeutics Inc. (CADL) to Buy
- Antero Midstream Partners LP (AM) PT Lowered to $22 at UBS
- Plains All American (PAA) PT Raised to $28 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
